Thank you for sharing this page.


EUA welcomes changes to Innovative Medicines Initiative (IMI) Funding Rules

14 December 2011

The Innovative Medicines Initiative (IMI Joint Undertaking) has announced important changes to its funding rules. Previously, the reimbursement of indirect costs in IMI-funded research projects was at a fixed rate of 20% of direct eligible costs. This was not economically viable and therefore unattractive for many potential participants, and was repeatedly criticised by many stakeholders, including EUA and EARTO (the European Association of Research and Technology Organisations).

In last week’s announcement, the IMI said that participants (including universities) may, alternatively, claim reimbursement on the basis of actual indirect costs. Furthermore, IMI’s funding rules have now also been further aligned with the European Commission’s Seventh Framework Programme (FP7) rules, by permitting the use of average personnel costs.

EUA Deputy Secretary General Dr John Smith said: “EUA welcomes these changes, which we believe should encourage much broader interest and participation in IMI research activities. In the light of this decision, EUA urges the European Commission to re-consider its recent Horizon 2020 proposals, which foresee the use of the 20% fixed rate reimbursement model for indirect costs that IMI has just abandoned.”

Please note that EUA’s previous statements on the IMI can be found here:

EUA’s first reaction to the European Commission’s proposals for Horizon 2020 can be found here.

European University Association (EUA)

Brussels office:
Avenue de l’Yser, 24
1040 Brussels
Tel: +32 (0) 2 230 55 44

Geneva office:
114, Rue du Rhône
Case postale 3174
1211 Geneva 3
Tel: +41 22 552 02 96